AZTREONAM FOR INHALATION SOLUTION (AZLI) TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA (PA) INFECTION

被引：0
|
作者：
Accurso, F. J. [1 ]
Fayon, M. [2 ]
Sermet, I. [3 ]
Lewis, S. [4 ]
Bresnik, M. [5 ]
Oermann, C. M. [6 ]
机构：
[1] UCD Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA
[2] CHU Bordeaux, CIC 0005, Bordeaux, France
[3] Hop Necker Enfants Malad, CHU Paris, Paris, France
[4] Gilead Sci Inc, Seattle, WA USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
[6] Baylor Coll Med, Houston, TX 77030 USA
来源：
PEDIATRIC PULMONOLOGY | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
    Elborn, J. Stuart
    Flume, Patrick A.
    Cohen, Fredric
    Loutit, Jeffery
    VanDevanter, Donald R.
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (05) : 634 - 640
  • [32] LONG-TERM STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (LAI) IN PATIENTS WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA INFECTION
    Konstan, M.
    Fajac, I
    Pressler, T.
    Clancy, J. P.
    Sands, D.
    Minic, P.
    Cipolli, M.
    Galeva, I
    Sole, A.
    Monroe, R.
    McGinnis, J. P., II
    Eagle, G.
    Bilton, D.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 270 - 270
  • [33] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    McKeage, Kate
    DRUGS, 2013, 73 (16) : 1815 - 1827
  • [34] Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
    Lam, John
    Vaughan, Steven
    Parkins, Michael D.
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2013, 7 : 61 - 77
  • [35] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Srilekha Panguluri
    Praveen Gunda
    Laurie Debonnett
    Kamal Hamed
    Clinical Drug Investigation, 2017, 37 : 795 - 805
  • [36] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Kate McKeage
    Drugs, 2013, 73 : 1815 - 1827
  • [37] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Panguluri, Srilekha
    Gunda, Praveen
    Debonnett, Laurie
    Hamed, Kamal
    CLINICAL DRUG INVESTIGATION, 2017, 37 (08) : 795 - 805
  • [38] Phase 3 trial (air-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)
    Retsch-Bogart, G. Z.
    Montgomery, B.
    Gibson, R.
    McCoy, K.
    Oermann, C. M.
    Cooper, P.
    PEDIATRIC PULMONOLOGY, 2007, : 310 - 311
  • [39] Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis
    Waters, Valerie
    Grimwood, Keith
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (03) : 292 - 293
  • [40] Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis
    Zemanick, Edith T.
    Bell, Scott C.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (06) : 636 - 645
12345